← All trials
NCT07221734
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Apr 30, 2027
- Completion date
- Feb 28, 2029
- First posted
- Oct 28, 2025
- Last posted
- Oct 28, 2025
- Enrollment
- 632
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Insud PharmaLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.